Overview
Severe tricuspid regurgitation (TR) is prevalent, particularly in elderly patients, and is associated with a poor prognosis 1. Transcatheter tricuspid valve interventions (TTVI) are an emerging option for patients with severe symptomatic TR who are at high surgical risk 1.
Diagnosis
Diagnosis of severe TR is typically made via echocardiography 1.
Further details on diagnostic criteria and grading are not provided in the abstracts.Management
Optimal medical therapy (OMT) is a treatment option for severe symptomatic TR 1.
Transcatheter tricuspid valve interventions (TTVI), including transcatheter edge-to-edge repair (TEER) and transcatheter tricuspid valve replacement (TTVR), are available for high-surgical-risk patients 1.
TTVI did not significantly reduce all-cause mortality, cardiovascular death, or hospitalization for heart failure at one year compared to OMT in a meta-analysis of three randomized controlled trials 1.
Tricuspid re-intervention rates were numerically lower with TTVI, though not statistically significant 1.Key Recommendations
Transcatheter tricuspid valve interventions (TTVI) did not significantly reduce all-cause mortality, cardiovascular death, or hospitalization for heart failure at one year compared to optimal medical therapy (OMT) in patients with severe symptomatic tricuspid regurgitation 1. (Evidence: Strong)
Transcatheter tricuspid valve interventions (TTVI) may lead to numerically lower tricuspid re-intervention rates compared to optimal medical therapy (OMT), though this was not statistically significant 1. (Evidence: Strong)References
1 Tartaglia F, Gitto M, Villaschi A, Calamita G, Stefanini G, Reimers B et al.. Transcatheter therapies for tricuspid regurgitation: A meta-analysis of randomized trials. International journal of cardiology 2025. link